Apollo Hospitals to Acquire IFC’s 31% Stake in Apollo Health and Lifestyle for ₹1,254 Crore

Apollo Hospitals Enterprise Limited announced on September 12, 2025, that it will fully consolidate its subsidiary, Apollo Health and Lifestyle Limited (AHLL), by acquiring the 31% stake currently held by the International Finance Corporation (IFC). The acquisition, valued at ₹1,254 crore, strengthens Apollo’s integrated healthcare model and expands its scope in oncology and lifestyle healthcare services.

Stake Acquisition of Apollo Health and Lifestyle

Upon completion of the transaction, Apollo Health and Lifestyle Limited will become a 99.42% subsidiary of Apollo Hospitals, with the remaining 0.58% held under the employee stock option plan (ESOP). The deal, subject to approval from the Competition Commission of India, is expected to close by November 2025. AHLL reported a consolidated turnover of ₹1,553.5 crore in FY25, with services spanning diagnostics, primary care, women’s health, dialysis, dental services and ambulatory care.

Investment in Gurugram Oncology Centre

Alongside the acquisition, Apollo Hospitals’ board approved an investment of ₹5,730 million to establish a new oncology centre at Gurugram. The facility will house the next-generation single gantry Proteus One Proton Beam Therapy system and is expected to serve an additional 350 patients annually.

This project forms part of Apollo’s second phase of expansion at Gurugram, following the successful rollout of phase one. The oncology centre is expected to be operational within four years.

Focus On Advanced Cancer Care

The Gurugram oncology initiative aims to address India’s growing cancer burden. Apollo’s expansion includes advanced therapies such as proton beam therapy, robotic surgery, high-end linear accelerators, immunotherapy, targeted therapies and genomics-based treatment. The centre will also provide bone marrow transplants and CAR T-cell therapies for blood disorders and complex malignancies.

With this acquisition and the oncology investment, Apollo Hospitals plans to double its oncology business to more than ₹5,000 crore over the next three to four years. The new Gurugram facility will be the third proton therapy centre in India, further strengthening Apollo’s position in advanced cancer treatment.

Read More: Apollo Hospitals to Double AI Investment Over the Next 2 to 3 Years

Conclusion

Apollo Hospitals’ ₹1,254 crore acquisition of IFC’s stake in Apollo Health and Lifestyle, coupled with a ₹5,730 million investment in advanced oncology care, positions the group to expand its integrated healthcare platform. With AHLL becoming a 99.42% subsidiary and a major oncology centre underway in Gurugram, Apollo is reinforcing its leadership in specialised healthcare and advanced cancer treatment.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.